Vanguard Group Inc Y M Abs Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,946,509 shares of YMAB stock, worth $9.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,946,509
Previous 2,000,022
2.68%
Holding current value
$9.23 Million
Previous $15.7 Million
44.94%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding YMAB
# of Institutions
105Shares Held
27.1MCall Options Held
38.4KPut Options Held
2.1K-
Paradigm Biocapital Advisors LP New York, NY4.24MShares$20.1 Million0.96% of portfolio
-
Acorn Capital Advisors, LLC New York, NY3.24MShares$15.3 Million9.97% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$13.9 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$10.4 Million0.72% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$8.68 Million0.05% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $207M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...